Published Date: 26 Apr 2023
The target population typically has better health than participants in health research studies, such as cancer screening trials (the "healthy volunteer" effect).
Read Full NewsThese were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.
As part of NeurologyLive®'s Year in Review, take a look at our top collaborative interviews with the Strategic Alliance Partnership program in 2025.
1.
For incarcerated people, study shows gaps exist in quality of cancer care
2.
Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer
3.
Ketamine plus psychotherapy for "excellent" PTSD
4.
Safe and acceptable telehealth suicide prevention program.
5.
Large, Grade 4 Kidney Tumors Pose Risk of Early Cancer-Specific Mortality
1.
Macrocytic Anemia: A Comprehensive Review of Pathophysiology, Diagnosis, and Clinical Management
2.
Unleashing Precision Medicine: CRISPR-Cas9 Gene Editing in Hematopoietic Stem Cells
3.
The latest Hematocrit: An Overview of Red Blood Cell Health
4.
Understanding Villous Adenoma: Causes, Symptoms, and Treatments
5.
Revolutionizing Cancer Treatment with Trilaciclib: How a New Drug is Transforming Outcomes
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
2.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
5.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation